Our flagship product is a nanoparticle-based contrast agent that is developed through a green route, offering numerous advantages over traditional gadolinium-based contrast agents.
At Knowledgepie, our mission is to innovate safer contrast agents for cancer detection and therapy, prioritizing patient safety, enhancing diagnostic precision, and redefining global cancer care through advanced research, ethical practices, and collaboration with healthcare professionals.
To translate ideas and research from bench to hospital, to make an
impact in oncology and to make significant contribution to the global fight against cancer.
Our developed technology is capped with biocompatible molecules and they form stable aqueous solutions, are non-toxic to normal cells, and show strong cytotoxicity against tumor cells compared to paclitaxel. Synthesis is facile, aqueous, thermo-free, and single-step.
It is produced using a green route, which means it is environmentally friendly and has minimal impact on the ecosystem.
As an iron-based agent, it carries no risk of nephrogenic systemic fibrosis (NSF) unlike Gd-based contrast agents (GBCAs).
Will be ‘First to market’ ‘Make in India’ product in contrast agent market.
Contrast agents play a crucial role in imaging applications like MRI by enhancing contrast. Conventional MRI contrast agents are primarily chelates of the rare earth element Gadolinium, which generate positive contrast on T1-weighted images. However, these agents can cause ghosting artifacts, hindering accurate diagnosis. Additionally, concerns regarding their potential toxicity remain unresolved.
The development of our advanced nanoparticle-based contrast agent offers a promising alternative to existing techniques, providing comparable or enhanced functionalities. This system demonstrates potential for simultaneous diagnosis and therapy while addressing the toxicity concerns associated with Gd-based contrast agents
